Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MJNA stock stair-stepping upward slowly from bottom. A good Q2 report around August 15th could help fuel the rise, imo.
You can watch next Tuesday's Senate mj hearing LIVE here:
https://www.judiciary.senate.gov/meetings/decriminalizing-cannabis-at-the-federal-level-necessary-steps-to-address-past-harms
My MJNA shares moved up a nice 25.56% today, and it's still cheap, imo.
AYRWF, too.
$AMMJ looks ready as the MJ sector is about to heat up with all the upcoming news.
Democratic senators are drafting legislation that would pair decriminalization of marijuana at the federal level with criminal justice reforms, and plan to introduce it as early as this week, lawmakers said.
https://amp.washingtontimes.com/news/2022/jul/19/democrats-see-opening-squeeze-marijuana-legislatio/
The Senate Judiciary Subcommittee on Crime and Terrorism, chaired by Sen. Cory Booker (D-NJ), will meet on July 26 for a meeting titled “Decriminalizing Cannabis at the Federal Level: Necessary Steps to Address Past Harms.”
https://www.marijuanamoment.net/senate-schedules-marijuana-hearing-in-committee-chaired-by-cory-booker-with-legalization-bill-set-to-drop-any-day/
SNDL Sundial Provides Update of Strategic Investment
CALGARY, AB, Jan. 6, 2021 /PRNewswire/ - Sundial Growers Inc.'s (Nasdaq: SNDL) ("Sundial" or the "Company") subsidiary special purpose vehicle that owns $51.9 million of aggregate principal amount of senior secured debt (the "Senior Loan"), such amount being inclusive of the payment referred to below, of Zenabis Investments Ltd. ("Zenabis"), a subsidiary of Zenabis Global Inc. (the "Parent") received a principal repayment of $7.0 million on December 31, 2020 (the "Payment") in accordance with the terms of the Senior Loan. Despite the Payment, a notice of default was delivered to Zenabis with respect to certain defaults under the terms of the Senior Loan. Zenabis is disputing said defaults.
All amounts are denominated in Canadian dollars.
ABOUT SUNDIAL GROWERS INC.
Sundial is a public company with Common Shares traded on Nasdaq under the symbol "SNDL".
Sundial is a licensed producer that crafts cannabis using state-of-the-art indoor facilities. Our 'craft-at-scale' modular growing approach, award-winning genetics and experienced master growers set us apart.
Our Canadian operations cultivate small-batch cannabis using an individualized "room" approach, with 448,000 square feet of total space.
Sundial's brand portfolio includes Top Leaf, Sundial Cannabis, Palmetto and Grasslands. Our consumer-packaged goods experience enables us to not just grow quality cannabis, but also to create exceptional consumer and customer experiences.
We are proudly Albertan, headquartered in Calgary, AB, with operations in Olds, AB, and Rocky View County, AB.?
Related Links
www.sundialgrowers.com
$RSCF Reflect Scientific Introduces Liquid Nitrogen Cooling Technology to Booming Cannabis Market
The company has released the Cryometrix L-80 liquid chiller, a new product for the cannabis extraction market.
Hemp Grower Link:
https://www.hempgrower.com/article/reflect-scientific-introduces-liquid-nitrogen-cooling-technology-to-cannabis-market/
$RSCF Year over year gains of 243% were realized for the period ending June 30, 2020 vs June 30, 2019. Gains are attributed to an increased demand for solvent chillers used in the cannabis processing market and a surge in bio-pharmaceutical manufacturing requirements for blast freezing and custom low temperature freezing solutions.
Sales to the hemp processing industry have been strong. The chillers are so efficient that many top tier companies have returned for repeat purchases for their divisions in the US and Canada. We are also Increasing our US / International reach through new distributor partner relationships.
American Weed stocks more on alert now than Canadian stocks
House passes bill decriminalizing marijuana at federal level..
https://www.cnn.com/2020/12/04/politics/house-vote-more-act-marijuana-legislation/index.html
Weed stocks on alert this week for nice gains
$CGC $CRON $ACB $TLRY $TCNNF
Ngw, a cannibus co. thats actually making profits.
https://investingnews.com/news/cannabis-investing/next-green-wave-continues-increase-in-both-profits-and-revenues/
Looking for MJ stocks to move up into the EOY
HI DARE, GOOD MORNING, 04-14-2020
$CBDL Next Ten-Bagger! CBD Play-News Expected_Soon_per_tweet $$$$$$
3 Pot Stocks Poised to Thrive in Ontario’s Revamped Retail Cannabis Market $NACNF $FFLWF $CGC)
https://www.thecannabisinvestor.ca/3-pot-stocks-poised-to-thrive-in-ontarios-revamped-retail-cannabis-market/
Thanks for posting/following CrazyKar123....
#davidlazar #reversemerger #mj #marijuana #hemp #custodian #custodianship
#merger #pennystocks $DCGD $ZMRK $KRFG $PASO $fcel $ACRL $PAOG $LAHO $VRUS
$VYST $SHMP $NWBO $ADIA $CNWHF $HMLA $ADIA $NVGT #marijuanastocks
$HPMM on alert, hot sector here!
https://hempofnaturals.com/
Liking this move so far on a few marijuana stocks so far today
2 Marijuana Penny Stocks to Watch includes OGI/MEDIF/LABS
Five reasons to buy cannabis stocks at these attractive levels
https://www.marketwatch.com/story/five-reasons-to-buy-cannabis-stocks-after-a-punishing-rout-2019-09-10
$TRTC On September 16, 2019, Terra Tech Corp. (the “Company”) issued a press release announcing that the Board of Directors has authorized the repurchase of up to $20,000,000 of the Company's common stock.
$MDCL - We are very pleased to welcome onto our team Robert Holmes and Steven Miller, two savvy and sophisticated operators, as well as their successful grow and retail stores.
Take a look at $MDCL >>> Medicine Man Technologies Expands its Retail Capabilities with the Planned Acquisition of Roots Rx, a Highly Reputable Operator with Six Dispensaries and Cultivation Facilities
Cannabis stocks turn higher after Curaleaf misses revenue estimates but offers bullish outlook #cannabis
#marijuanastocks #weedstocks #cannabiswatch
https://www.transparenttraders.me/2019/09/cannabis-stocks-turn-higher-after.html
$CBDY is Vertically Integrated
Target is building an exclusive portfolio of cannabis companies, across the entire seed-sale value-chain.
http://www.targetgroupinc.ca/
$MJTV Loading Zone! CBD Acquisition news on the way!
$GBHL Undiscovered MJ Play! Weedweb news on the way!
Funding/JV Partner News expected on their WeedWeb Professional Cannabis Network application:
http://www.global-gbhl.com/
Global Entertainment Holdings, Inc. ($GBHL) Owner of WeedWeb.com launches new website.
https://www.reddit.com/r/CannabisStock/comments/ax8njn/global_entertainment_holdings_inc_gbhl_owner_of/
$APYP Hemp Based CBD Infused Beverage Product Company:
AppYea, Inc. Enters into Management Agreement with Hempori, Inc.
Fort Worth, TX , Jan. 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AppYea, Inc. (OTCPK: APYP, or the "Company") is pleased to
announce that is has entered into a management agreement with Dallas, TX based management company Hempori, Inc. (“Hempori”) which
will assist the Company in identifying and managing potential investments that the Company is seeking to make in various ventures
and opportunities in the CBD Cannabidiol & Hemp Industry sectors.
https://www.otcmarkets.com/stock/APYP/news/story?e&id=1271410
AppYea, Inc. Enters into CBD Distribution Agreement
FORT WORTH, TX, Feb. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Appyea, Inc. (OTCPK: APYP, or the "Company") is
pleased to announce that is has entered into a distribution agreement with Dallas, TX based Hempori, Inc. (“Hempori”)
which will allow Appyea, Inc. to source new CBD based products and services to be sold and distributed through Hempori’s
distribution channels and retail stores bringing a new revenue stream to the Company.
https://www.otcmarkets.com/stock/APYP/news/story?e&id=1277874
AppYea, Inc. Signs Exclusive CBD Infused Beverage Licensing Agreement
Ft. Worth, Texas, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AppYea, Inc. (OTCPK:APYP, or the "Company") is
pleased to announce that is has entered into an exclusive CBD infused beverage licensing agreement with Prouty Company, Inc. (“ProutyCo”).
The CBD infused beverage product line in development is based on four categories which are energy, focus, calm, and sleep. These are known
as functional beverages and are a brand-new class of product.
https://www.otcmarkets.com/stock/APYP/news/story?e&id=1284513
AppYea, Inc. Fulfills First CBD Purchase Order
Fort Worth, Texas, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AppYea, Inc. (OTCPK:APYP, or the "Company"),
which previously announced its move into Hemp based CBD infused products, announced today that the company has received
and fulfilled its first purchase order from Hempori, Inc. (“Hempori”). The purchase order is for various skus of hemp
derived CBD infused products.
https://www.otcmarkets.com/stock/APYP/news/story?e&id=1288174
AppYea, Inc. Engages Smalltell, a Social Commerce and Design Company
Fort Worth, Texas, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AppYea, Inc. (OTCPK:APYP, or the "Company"),
announced today that the company has engaged Smalltell (Smalltell.com) to develop a new website and marketing strategy
for its new CBD based line of products. Smalltell will also assist in the creation of the new CBD beverage brand and design.
https://www.otcmarkets.com/stock/APYP/news/story?e&id=1290887
Ticker Buzz Cloud (24 hours)
Time Interval: 24hr | 12hr | 6hr | 3hr | 1hr
ACB ACB ADSV ADXS AMFE ANWWQ ANY APYP ARYC BBDA BIG BOTY BRKK CBBT CMGO COBI
COOP COOP CRSM CVS DVLP EPAZ FNMA FTEG GBHPF GETH GNCP HAS HEMP HHSE ICNB III
IMO LOW LYFT MCOA MLHC NIO NWBO ONCI PGUS RETC RSHN RUN SBES SHMP SOLI SPRV VIBI
VRUS VSTR VYST WWIO
Blue Moon's creator launched a cannabis beer that sold out in 4 hours
Zack Guzman
Senior Writer
Yahoo FinanceMarch 25, 2019
Keith Villa achieved a Ph.D. in brewing sciences at the University of Brussels, launched what many consider to be a craft beer pioneer in Blue Moon, and had just retired after a 32-year career at America’s second largest beer maker Molson Coors.
But he just couldn’t bring himself to hang up the brewing cleats as he watched the cannabis wave hit Colorado.
Twenty-four years after Villa finished his most famous recipe for the new beer at Coors Field that came to be called Blue Moon, he’s expanding his own brewing operation and line of cannabis beers that appear to be just as pioneering.
Just four hours after debuting his new Ceria Brewing Co. non-alcoholic, marijuana-infused, Belgian-style ale in Colorado dispensaries last December, it sold out.
ARVADA, CO - MARCH 29: Keith and Jodi Villa pose for a picture at the headquarters for Ceria Beverages on Thursday, March 29, 2018. Keith Villa is the creator of Blue Moon, the popular Belgian-style white beer produced by Coors. The Villas are working under their brand Ceria to create what they believe is the first ever THC-infused non-alcoholic beer. They plan to release their first batch by the end of 2018 in Colorado then expect to expand to Nevada, California and Washington in the coming year. (Photo by AAron Ontiveroz/The Denver Post via Getty Images)View photos
Keith Villa is the creator of Blue Moon, the popular Belgian-style white beer produced by Coors. The Villas are working under their brand Ceria and expect to expand to Nevada and California in the coming year.
More
“It turns out a lot of cannabis products are popular for Christmas gifts,” he told Yahoo Finance YFi PM, adding that he’s seeing more and more first-time cannabis users as customers. “You don’t taste cannabis you taste great tasting beer with the effects of cannabis and that’s really critical because we found that the taste of cannabis is really polarizing. Some people love it, but most people don’t really care for it.”
That fact is at least partially responsible for the incredible growth forecasts analysts are projecting for the cannabis space in the years ahead. According to BDS Analytics, beverages made up only about 5% of the annual U.S. edibles market, with sales of $30 million. By 2022, cannabis beverage sales are expected to expand by more than 10-fold, to $374 million.
That growth opportunity has attracted more than just Villa’s Ceria Brewing Company. His beer now joins first mover Cannabiniers’ Two Roots brand of THC-infused beers in the race against the brewing behemoths, which have increasingly partnered with Canada’s leading marijuana companies. Corona importer Constellation Brands invested $4 billion in cannabis company Canopy Growth to pursue development of cannabis-infused non-alcoholic beer for sale in Canada by October when they are slated to be legalized. Molson Coors set up its own joint venture with Canadian cannabis company Hexo Corp. to pursue the same goal.
But there is a little-known legal distinction in the law that Villa said might help his smaller non-alcoholic beer venture take on the brewing giants.
“A lot of people don’t realize that cannabis is legal federally in Canada right now, but only the smokable forms,” he said. “Drinkables become legal this October ... [but] part of the ruling in Canada is you cannot use any existing logos or names of beverage companies that are associated with alcohol.”
Separating from the pack
Similar to Two Roots, Ceria is looking to establish brand power by expanding to multiple states in the U.S. before the major brewers introduce their products in Canada. Villa said overwhelming demand for his first batch led to not only building out his Colorado operation in March, but also his decision to expand distribution to California and Nevada dispensaries within the next three months.
Due to federal restrictions on interstate cannabis commerce, Ceria will distribute the non-alcoholic beer base across state lines before infusing batches with THC in each state ahead of bottling. State and federal law both prohibit combining alcohol and marijuana in beverages for sale.
$KALY Cannabis Patent Featured In PURA Report On Progress Toward $5 Million Sales Goal
DALLAS, March 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced the company’s recent advances developing a CBD extract for infusion into a beverage at a 25 mg concentration were featured in a report published yesterday by Puration, Inc. (PURA) (“PURA”). PURA yesterday reported recent progress toward the company’s $5 million 2019 sales goal. The report included an overview of KALY’s role using its patented extraction process to develop a CBD extract that will sustain suspension in a beverage at a consistent concentrate level of 25 mg. The first target beverage for the 25 mg CBD concentrate beverage is a private labeled health water for Generex Biotechnology (GNBT).
Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY is utilizing its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.
In addition to the wellness products KALY is working on with PURA, KALY has a report soon to be published on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
$PAOG Newest MJ Company Ready to Run!
$PAOG MJ Money Will Flood To PAOG --->>
https://finance.yahoo.com/news/pao-group-proudly-announces-mj-191835151.html
ACB & CRON Mega pre-earnings runs continue
$CADMF The Warren Buffett Weed Play
One Company Is Following Warren's Formula and Investors Could Reap Berkshire Returns
By J. Daryl Thompson
The market is LOADED with opportunities for savvy investors to make a fortune in marijuana! And thanks to an increased push towards legalization in many states, there’s a LOT of untapped potential.
We’re seeing niches within the marijuana industry EXPLODE!
Companies are specializing from cultivation to distribution, to processing and manufacturing, and of course, to retail sales to consumers who are ‘patients’ and casual indulgers.
American exceptionalism is once again producing amazing companies!
However, most of those companies are too focused on one niche of the marijuana boom. They’re missing the Warren Buffett rule… and it could cost them millions.
But there’s ONE company who’s following Buffett's rule: Chemesis International (OTC:CADMF) (CSI:CSE)
Sponsored
Innovation from Seed To Sale Gives Investors MAJOR Upside
In the exploding Marijuana market, the ability to control costs from cultivation to retail sales has only upside. Where most companies in the marijuana industry lose profits is here… but Chemesis is the ONE company that can actually GROW profits!
See Where You Could Invest In Chemesis HERE
What Would Warren Do In Marijuana?
Warren Buffett’s approach is a simple one, and one that’s made him and his investors VERY rich.
Warren’s investing rule says “buy quality stocks at rock-bottom prices”. His real goal is to build more and more operating power for Berkshire Hathaway by owning stocks that will generate solid profits and capital appreciation for years to come.
The only one (at least that I know of) that is taking the Warren Buffett approach and hedging across multiple niches within an exploding sector is Chemesis (OTC:CADMF) (CSI:CSE). As a first-mover in the cannabis industry with worldwide reach, it operates in the most important and profitable sectors of the cannabis industry.
Chemesis is a company that is focused on acquiring growth potential companies within the Cultivation, Manufacturing, Delivery, AND Retail sectors. All of them reside under one conglomerate company, Chemesis International. They deliver strong management, global connections, experience in each niche, AND access to the coming flood of venture capital.
They are building brands and successful companies for more operating power, which makes for solid profit potential in the EXPLODING marijuana sector.
Warren would be proud!
A Marijuana Blue Chip Conglomerate
You see, Chemesis saw the opportunities in marijuana, but they also realized the RISK. So they did what Warren would do… hedge.
They researched 5 of the most profitable growth sectors of the industry, including cultivation, packaging, transportation, branding and retail, and acquired companies in these spaces who on their own were successful, but TOGETHER with a full leadership team looking at multiple aspects can bring massive profitability to each.
Chemesis International has a fully compliant state-of-the-art manufacturing facility that is 35,000 ft² and has a license to cultivate 100,000 ft² of cannabis. This rivals any in the market today. Chemesis currently has the capacity to produce 30,000+ lbs of cannabis per year and 90 kilos of crude oil per day. They also have multiple expansion opportunities in California, Columbia, and Puerto Rico.
Chemesis also owns Desert Zen, a manufacturing, transportation and distribution company, that has passed California’s stringent cannabis transportation laws. What’s more, they are able to track, monitor and ensure that all seed-to sale laws are followed throughout their business vertical. Desert Zen has even begun servicing other producers and brands throughout the region.
In August 2018, Chemesis International purchased an 80% interest in Natural Ventures, a seed-to-sale medicinal cannabis company in Puerto Rico, as well as SAP Global, an oil production facility in California. SAP Global is known for its high-quality oil-based products throughout the west coast. It has been the recipient of 26 awards in the past seven years.
Sponsored
Chemesis Scores Market Moving Brands
Chemesis controls or has exclusive partnerships with six high recognition brands with followings in the TENS OF MILLIONS on social media. When customers shop at ANY of the multi-state retails shops, they won’t miss one of the Chemesis brands, turning those purchases into investor profits!
Learn More About Chemesis Brands HERE
Recent Acquisitions and Buyouts
Chemesis announced last year that they have come into partnership with Rapid Dose Therapeutics (RDT), a Canadian bio-technology company providing disruptive proprietary drug delivery technologies designed to improve patient outcomes, with a novel proprietary therapeutic delivery system QuickStrip™ Oral Thin Strips to Puerto Rico and California.
At the end of the year, Chemesis International Inc. (OTC:CADMF) (CSI:CSE) made another acquisition and entered into a binding Letter of Intent to acquire 100% of Colombia-based La Finca Interacviva-Arachna Med SAS (La Finca), an integrated cannabis company licensed and operational in Colombia since 2017. La Finca has over 1,000 acres of outdoor cannabis cultivation and is aggressively exploring expansion opportunities throughout the country.
After securing the Puerto Rican and Colombian cannabis markets, CFN Media Group -- the leading agency and financial network of the North American cannabis industry -- published an article calling out the emerging Latin American market and specifically recognized Chemesis Latin America, Chemesis International’s new subsidiary, focusing on their disruption of Central and South American cannabis markets.
Along with their Latin American acquisition, Chemesis International has obtained a full line of CBD products, which are for sale in the U.S. Their Viverian line of CBD products are available for purchase in Arizona, Nevada, and Florida. The products are lab tested, THC free, and made of 100% botanical ingredients, all manufactured from a third party GMP certified facility.
Mainstream Weed Could Be Worth TRILLIONS
Even though North America has been stealing the spotlight the last few years, most of the fastest growing cannabis stocks are located to the North, in Canada where cannabis was recently legalized across the country. Cannabis is on pace to become a $10.8 billion industry by the end of 2019, with thousands of investors entering the market every day. Estimations for cannabis reach as high as $194 billion by 2026, and some believe has the potential to reach $1 trillion.
“Chemesis Latin America is a big step forward in our global growth strategy,” said CEO Edgar Montero
Sponsored
What Fully Compliant Distribution REALLY Means for Chemesis…
With the ability to cultivate over 30,000+lbs of product and manufacture 2,000 lbs of raw material into products and oils, Chemesis could supply the ENTIRE USA...but without the legal distribution, they’d be dead in the water. But they’ve partnered with a FULLY COMPLIANT distributor who can take their product into ANY state that can sell medicinal or recreational products produced by Chemesis.
It means the more states that get legal, they can INSTANTLY profit from product sales because they can LEGALLY deliver!
?Learn More About Chemesis's unique distribution process.
While Canada and the United States have stolen the media show, the opportunity in Latin America, which has been flying under the radar, is about to explode. Prohibition Partners believes that the Latin American cannabis industry will soon grow from $125 million in revenue this year to $12.7 billion by 2028. Many countries in South America like Puerto Rico and Columbia have legalized cannabis and struck exclusive production deals with select companies, like Chemesis International Inc. (OTC:CADMF) (CSI:CSE).
Now is the time to buy-in the ever-growing cannabis boom that is spreading like wildfire throughout not just our country, but nearly the entire western hemisphere. Many of the biggest opportunities lie just to the north, and now to the south, of our borders. Big money from hedge funds and blue-chip corporations like Constellation Brands, the producer of Corona and Modelo, as well as Coca-Cola, are striking deals with cannabis companies, giving immense overnight returns to investors. These same gigantic returns are about to hit companies like Chemesis, which have cornered their markets.
For example, Aphria went from a market cap of $313 million to $4.3 billion after firms Vanguard, Credit Suisse, RBC and BlackRock backed up their cash trucks and put their money down. The same happened to Aurora Cannabis, who went from a cap of $760 million, before Horizons Investment Management came in. Then followed investments from Goldman Sachs, Deutsche Bank, and UBS. Aurora’s stock skyrocketed, rising as high as 641% in a few weeks. Today, we’re witnessing a cannabis company with a market cap of $11.7 billion, an increase of 1,539%.
Given the explosive growth that Canadian companies have experienced in the 4th quarter of 2018 as they’ve gained huge investments from American companies and hedge funds, investors are getting nervous. With average valuations at 253 times earnings for the top four producers, it’s going to take a company that is willing to diversify and incorporate themselves into the U.S. market to hold on to their value. Certainly, all of the winners to date won’t, but more will, and they will require a different approach outside of heavily relying on cultivation, which is about to become a commodity-traded industry. That’s why the most recent cannabis stock fluctuations are caused by speculation that cannabis producers are diversifying into markets like beverages, dispensaries, distribution and branding.
The Chemesis International Inc. (OTC:CADMF)(CSI:CSE) model is based on diversification and following the Berkshire Hathaway model of streamlining companies into one business vertical. This allows them to profit at all levels of their own business-cycle and take profits from other cannabis companies with their own manufacturing, packaging and transportation arms to service other cannabis producers.
So why haven't many consumers heard of Chemesis?
Until recently, they’ve been focusing on growth! Berkshire wasn’t built in a day, and due to their unique business model, being positioned as a conglomerate in the industry like Procter & Gamble, Nestle or Berkshire Hathaway, it’s been head-down focused on growth. Chemesis has been buying out companies who are concentrated on the five most highly profitable and fastest growing cannabis sectors in the country.
And now, their model has come together to produce what could be an industry game-changer, and the first of its kind! This could produce huge rewards for their early investors.
$KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
Date : 01/25/2019 @ 10:00AM
Source : InvestorsHub NewsWire
Stock : Kali, Inc. (PN) (KALY)
Quote : 0.0114 0.0008 (7.55%) @ 3:59PM
KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
Print
Alert
Dallas, TX -- January 25, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online corporate update scheduled for Wednesday next week on January 30, 2019. The presentation will include updates on KALY’s developments with Puration, Inc, (USOTC: PURA) (“PURA”) and Generex Biotechnology, Inc. (OTCBB: GNBT). The presentation will also include updates on the company’s Hemp4mula product developments. The highlight of the presentation will feature the latest on the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD). KALY has completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. Favorable results prompted the launch of a physiological study whose results will be released later this quarter. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
Goldman Small Cap Research Report published an analyst research report on KALY on January 8th, 2019 that highlights KALY’s cannabis pharmaceutical value. The report is available under “research” on the OTCMarkets website. The research report is the first report from Goldman Small Cap Research as part of an ongoing research engagement. The report outlines the company’s current positioning and potential, upcoming milestones. The report is intended to augment the current information available on the OTCMarkets website. The report is also available to read or download, along with associated disclosures and disclaimers, at www.GoldmanResearch.com.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Top Marijuana Stocks to Watch
BY MRINALINI KRISHNA Updated Jan 14, 2019
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2022 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. The research projects a majority of that, nearly $23.4 billion will come from the United States. In context of more states voting in favor of marijuana use legalization and business interest sparking across the board, that definitely would make sense.
In the year through January 11, 2019, the United States Marijuana Index, fell 20.7%, as compared to about 6.5% loss seen by the S&P 500. Given that is not exactly an apples to apples comparison, but it does make a case to at least investigate investments in marijuana stocks.
But before you open your wallet to get a piece of the action, here are a few things that could help you.
(See also: Waiting to Exhale: The Case for Cannabis Investing)
Marijuana Regulation & Why It Matters
While our northern neighbors legalized marijuana as of October 17, 2018, it remains illegal and classified as a Schedule I drug under Controlled Substances Act at the federal level in the United States. However, with more and more states voting to make cannabis usage lawful in some form, marijuana regulation essentially is a hot mess.
In the November midterm elections, the following states voted in favor of marijuana legalization for either recreational or medicinal purposes, or both:
Michigan: Voters approved Proposal One, which legalizes marijuana use and cultivation for people over the age of 21 in addition to authorizing the commercial sale of marijuana through state-licensed retailers.
Missouri: Voters approved Amendment 2, which permits the use of marijuana for medical purposes and allows patients to cultivate plants at home. Marijuana was not approved for recreational use.
Utah: Voters approved Propostion Two, which allows some use of marijuana for medical purposes, only.
On June 26, 2018 Oklahoma voted to in favor of legalizing marijuana for medical use, becoming the 30th state in the country to do so. But validity of these state laws depends on the stance of the federal government that has not quite landed firmly on one side.
In January of 2018, former Attorney General Jeff Sessions, a vocal opponent of marijuana legalization, rescinded an Obama-era rule that gave states a greater role in marijuana law enforcement though it conceded that states could not come in the way of any federal enforcement action. The 2013 guidance issued by the Attorney General James Cole, came to be known as the ‘Cole Memo’.
President Trump himself has changed his stance a few times, going from calling recreational marijuana ‘bad’ back in 2015 as a candidate to committing to Colorado Senator Cory Gardner in April this year to support a federalism-based legislative solution to fix this states’ rights issue once and for all.
The state of regulation will, needless to say, determine the fate of this industry. As the legal boundaries exist today, many companies are witnessing exponential growth on the back of surging demand and interest. This momentum could continue till there is more clarity on regulations.
Where Are Marijuana Stocks Listed
Canada Listed vs U.S. Listed:
This uncertainty in the regulatory framework has not only impacted business operations for companies in the sector but has also seen fewer listings in the United States. In fact, there have been cases where American companies have gone north in search of more welcoming environment for their stock market debut. California-based MedMen is an example, as reported by CNBC.
OTC Markets vs NYSE/NASDAQ:
Both major American stock exchanges the NYSE and Nasdaq saw their first purely cannabis companies list in 2018. The Cronos Group became the first to make its trading debut on Nasdaq in February, while Canopy Growth Corp. became NYSE’s first pot listing in May.
Even as the bigger exchanges open up to companies in this space, a large number of companies remain penny stocks being traded primarily in the OTC Markets, increasing both skepticism as well as risk perception of any investment.
What to Watch Out For
As with any other investment, investors must do their homework before they place their bets. That can be hard, since a lot of these companies trade in the OTC Markets with less stringent filing and disclosure requirements compared to the larger exchanges. It can also be difficult to understand business models and source information about investments since the industry is still young and still not mainstream.
"Just because a cannabis company is trading on the OTC Markets Group, that doesn’t mean that they’re a sketchy stock, it just only means that it’s the only place that they could go. So there are some good names in the OTC Markets group, so don’t let that scare you away. And having said that, there are some less than stellar names in the New York Stock Exchange trading there," said Debra Borchardt, Founder and Editor-in-chief of Green Market Report. (See also: Investopedia Webinar on Cannabis Investing with Debra Borchardt)
Let's take for example Insys Therapeutics (INSYS), an Arizona-based Nasdaq-listed pharmaceutical company that was betting big on cannabinoid oil based drug to treat loss of appetite in people suffering from AIDS and nausea and vomiting caused by chemotherapy and anti-cancer medicine. The company received the FDA approval for its drug Syndros in 2016. However, its stock took a beating from its 2015 highs of $44/sh to near $4.00/sh in October 2017 when company executives were charged with offering kickbacks to doctors to prescribe its fetanyl-based drug Subsys. (See also: Insys Owner, Pharma Billionaire Arrested For Opioid Racket)
Borchardt also gives an example of The Green Organic Dutchman Holdings Ltd. (TGODF), the Ontario, Canada-based company that listed on Toronto stock Exchange on May 2, 2018 that has seen its shares fall 21.4% since then. The interesting thing is that he company has no revenue. Investors would need to factor that in before making a decision of investing in the company.
Types of Marijuana Stocks
If you want you could choose to invest in a ‘plant-touching’ company or a company that is strictly in the business of medical marijuana. You could also ride the wave by investing in the companies that benefit but don’t necessarily engage in the pot business directly. Here’s a look at some of these stocks. All financial and market capitalization figures, unless specified, are from Yahoo Finance as of June 29, 2018.
Plant Touching/Cultivation Operations:
Canopy Growth Corp. (CGC): Market Cap: $13.1B
The first Canadian marijuana unicorn, Canopy Growth Corp. listed on the NYSE in May, becoming the world's largest publicly traded weed company. The company owns and operates many brands, producing and marketing both medical and recreational strains. 'Tweed' is one of the company's most popular brands on account of its association with rapper turned marijuana entrepreneur Snoop Dogg. For the fiscal year ended March 31. 2018, the company reported revenue of CAD 77.9 million or nearly $60 million. In October 2017, Constellation Brands, beverage giant and maker of Corona beer, bought 9.9% stake in Canopy Growth. The deal opens up both companies to new product lines such as cannabis-infused beverages.
Average Volume: 10,325,804
Market Cap: $13.1B
P/E Ratio (TTM): N/A
EPS (TTM): -$1.79
Aurora Cannabis Inc. (ACB): Market Cap $6.37B
Another big Canadian pot company, Aurora Cannabis became even bigger in March by acquiring rival MedReleaf in a $.25 billion all stock deal, touted as the largest marijuana deal in the world. Consolidating operations will help the new entity cut costs and gain efficiency. According to a press release, Aurora and MedReleaf together expect to produce over 570,000 kilograms per year of cannabis through nine facilities in Canada and two in Denmark. Aurora debuted on the Canadian venture stock exchange (TSX) in October 2016 and trades in the US in the NYSE.
Average Volume: 15,100,703
Market Cap: $6.37B
P/E Ratio (TTM): N/A
EPS (TTM): $0.22
Cronos Group Inc. (CRON): Market Cap $2.44B
Nasdaq's first pot stock Cronos Group is a Toronto-based cultivator of medical marijuana. In addition to Canada, Cronos serves an international market. It ships its products to Germany, is building a facility in Israel and has a license through a joint venture in Australia. While it does not have a presence in the United States due to the uncertainty in regulations, as of the fiscal year ending March 31, 2018 the company generated $2.2 million in revenue.
Average Volume: 10,780,493
Market Cap: $2.44B
P/E Ratio (TTM): N/A
EPS (TTM): -$0.03
Terra Tech Corp (TRTC): Market Cap $83.14M
Incorporated almost a decade ago, Terra Tech is diversified agricultural company that has operations in production and dispensing medical marijuana as well as hydroponic equipment for other agricultural products. Its own medical marijuana brand is IVXX, while its cultivation takes place under the brand name Edible Gardens. The company also operates retail distribution of medical marijuana under the name Blum. The OTC Markets listed company, has operations in the U.S. including a State of California Temporary Authorization to cultivate, manufacture, distribute and retail cannabis to the adult-use market. It has Blum dispensaries in Nevada and has two large cultivation facilities in the stae where production will commence after necessary State approvals. In its latest earnings report, the company declared revenues of $8.6 million for the quarter ending March 31, 2018.
Average Volume: 1,029,804
Market Cap: $83.14M
P/E Ratio (TTM): N/A
EPS (TTM): -$0.74
Pharma/Biotech
AbbVie (ABBV): Market Cap $132.9B
AbbVie is a pharmaceutical company but with a synthetic cannabis-based drug on the market. The FDA approved Marinol, which helps alleviate nausea or vomiting for chemotherapy patients. The drug also helps AIDS patients who have lost their desire to eat. It is important to note that Marinol is not AbbVie's flagship drug. In fact, it is not even the company's biggest seller. That makes investing in this company,is a way to play the marijuana trend without incurring 100% exposure to the plant.
Average Volume: 5,318,114
Market Cap: $132.9B
P/E Ratio (TTM): 18.44
EPS (TTM): $4.79
Dividend and Yield: $4.28 (4.85%)
GW Pharmaceuticals (GWPH): Market Cap $4.06B
A big win for U.K.-based GW Pharmaceuticals came on June 25, 2018 when the FDA approved the first of its kind drug derived from an active marijuana ingredient as opposed to synthetically derived cannbinol compounds. The drug, Epidiolex, has been approved for treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. The company is listed on Nasdaq as an American Depository Receipt (ADR).
Average Volume: 463,151
Market Cap: $4.06B
P/E Ratio (TTM): N/A
EPS (TTM): -$10.61
Cara Therapeutics (CARA): Market Cap $624.4M
This clinical-stage biotechnology company develops drugs for treatment of Pruritus and acute and chronic pain. Its product pipeline include both opioid as well as cannabinoid drugs. However, the CB agonist CR701 that makes it eligible for this list is still in its pre-clinical trial phase and a lot rides on the outcome of the trials before the stock could get a high from pot.
Average Volume: 598,427
Market Cap: $624.4M
P/E Ratio (TTM): N/A
EPS (TTM): -$1.98
Axim Biotechnologies (OTC:AXIM): Market Cap $80.4M
This biotech company is working on at least 16 drugs in varying stages of pre-clinical and Phase I & II of clinical trials. These drugs are aimed are treatments for a number of different ailments ranging from dry eyes, inflammatory bowel disease, opioid addiction and even smoking cessation.
Average Volume: 87,061
Market Cap: $80.4M
P/E Ratio (TTM): N/A
EPS (TTM): -$0.129
Ancillary Businesses:
The Scotts Miracle-Gro Company (SMG): Market Cap $3.76B
Two years ago, Jim Hagedorn, the CEO of the lawn care and garden supplies company decided to make a huge push into pot through hydroponics. In a Forbes profile titled 'Cannabis Capitalist', he said he wanted to invest half a billion dollars into hydroponics and he didn't disappoint. In fact, earlier this year the company acquired hydroponic equipment maker Sunlight Supply Inc. in a deal valued at $450 million.
Average Volume: 579,075
Market Cap: $3.76B
P/E Ratio (TTM): 61.1
EPS (TTM): $1.11
Dividend and Yield: $2.20 (3.26%)
KushCo Holdings (OTC:KSHB): Market Cap $569.4M
Founded in 2010, Kush Bottles provides packaging solutions and supplies, vaporizers as well as branding services to cannabis producers. The company operates across 12 facilities in the U.S. and as of Q2 2018(recorded in February 2018) reported revenues of $10.6 million.
Average Volume: 612,696
Market Cap: $569.4M
P/E Ratio (TTM): N/A
EPS (TTM): -$0.26
GrowGeneration Corp (OTC:GRWG): Market Cap $74.6M
This agriculture solutions company, owns and operates specialty hydroponic and organic gardening supplies stores in 17 locations across six states. These stores sell nutrients, soil, lighting and hydroponic solutions. The company that generated $14.2 million in revenue last year, in its investor presentation aims to turn profitable by Q2 2018 and its targeting $84.6 million in revenue by 2020.
Average Volume: 108,965
Market Cap: $74.6M
P/E Ratio (TTM): N/A
EPS (TTM): -$0.20
Marijuana-Business Related Services:
General Cannabis Corp (OTC:CANN): Market Cap $83.3M
The company provides a whole host of ancillary services to producers and businesses in the marijuana industry, ranging from real estate, consulting, business development and even security. The Denver, Colorado-based company even owns a specialty cannabis lifestyle apparel under the brand Chiefton Supply Co.
Average Volume: 298,173
Market Cap: $83.3M
P/E Ratio (TTM): N/A
EPS (TTM): -$0.46
Innovative Industrial Properties Inc.(IIPR): Market Cap $506.2M
This is a medical marijuana focused Real Estate Investment Trust (REIT). As of December 31, 2017, it owned five properties located in New York, Maryland, Arizona and Minnesota, totaling approximately 617,000 rentable square feet. Its investment at the end of last year stood at $68.3 million.
Average Volume: 235,526
Market Cap: $506.2M
P/E Ratio (TTM): 86.2
EPS (TTM): $0.60
Dividend and Yield: $1.40 (2.72%)
mCig Inc. (OTC:MCIG): Market Cap $102.62M
This diversified holding company operates in wide ranging areas of the marijuana industry. Its portfolio spans technology and consulting, products including vaporizers, media assets, growers and cultivators and even dispensaries.
Average Volume: 1,052,701
Market Cap: $102.62M
P/E Ratio (TTM): N/A
EPS (TTM): $0.0040
Sin Stocks Riding Cannabis Wave:
With pot's growing popularity and increasing number of states moving towards legalizing it in some form, traditional vice companies like big tobacco and alcohol began to worry about its impact on their sales. Since they couldn't beat the marijuana wave, they decided to join it. In May this year, a Moody's report said that alcohol and tobacco sales could suffer with growing pot sales but also identified that as a potential opportunity for these companies to create new product lines.
"As marijuana is legalized, it could replace alcoholic beverages on some drinking occasions, but also be used to formulate new beverages. At a time when cigarette smoking is on the decline, we expect that US tobacco companies will enter the US marijuana market, but only if marijuana becomes federally legal," said the report.
These companies have already begun to do just that.
Constellation Brands (STZ): Market Cap $30.2B
Not only did the maker of Modelo beer and Svedka invest $190 million to buy nearly 10% stake in Canopy Growth, work has actively begun towards realizing cannabis-infused non-alcoholic beverages. Canopy's CEO Bruce Linton in the earnings call in June 2018, spoke about the company contemplating packaging solutions for beverages and is confident of being ready for the market by next year. "I think we're on track to be very ready for all of the formats in 2019," he said.
Average Volume: 2,513,064
Market Cap: $30.2B
P/E Ratio (TTM): 10.03
EPS (TTM): $15.87
Dividend and Yield: $2.96 (1.96%)
Heineken N.V. (OTC:HEINY): Market Cap $50.6B
The European beverage giant's latest offering in the pot-infused product market is the Lagunitas' IPA-inspired and THC and CBD infused sparkling water called Hi-Fi Hops. Heineken completed the Lagunitas acquisition in 2017, after initially taking a 50% stake in the company. Lagunitas has tied up with medicinal marijuana company CannaCraft to add the THC/CBD ingredients to the product that will be distributed initially through dispensaries in California.
Average Volume: 79,113
Market Cap: $50.6B
P/E Ratio (TTM): 21.64
EPS (TTM): 2.06
Dividend and Yield: $0.68 (1.54%)
Molson Coors Brewing Company (TAP): Market Cap $13.7B
Molson Coors has been pretty vocal about the impact of legal pot on its business. Earlier this year, the company in its SEC filing listed legal marijuana as a risk factor to its business stating, "although the ultimate impact is currently unknown, the emergence of legal cannabis in certain U.S. states and Canada may result in a shift of discretionary income away from our products or a change in consumer preferences away from beer."
According to a June 2018 BNN Bloomberg report the company is in talks with four cannabis companies including Aurora Cannabis and Aphria Inc. (OTC: APHQF) to develop cannabis-infused beverages.
Average Volume: 2,091,835
Market Cap: $13.7B
P/E Ratio (TTM): 8.43
EPS (TTM): $7.52
Dividend and Yield: 1.64 (2.61%)
$LVVV LiveWire Ergogenics Granted Approval for Minor Use Permit to Establish Large-Scale Nursery
Date : 01/22/2019 @ 6:00AM
Source : InvestorsHub Cannabis NewsWire
LiveWire Ergogenics Granted Approval for Minor Use Permit to Establish Large-Scale Nursery
Anaheim, CA -- January 22, 2019 -- InvestorsHub NewsWire -- LiveWire Ergogenics, Inc. (OTC: LVVV) announced today that its subsidiary GHC Ventures has been granted a Minor Use Permit from the County of San Luis Obispo Department of Planning and Building to begin build-out and production in its 22,000 square foot Nursery facility in Paso Robles, California. LiveWire Ergogenics, Inc. is a company focused on the acquisition, licensing and management of special-purpose real estate properties and the development and leasing of compliant turnkey production facilities for licensed cannabis-based operations.
The Minor Use Permit has been issued to establish a 22,000 square foot secure indoor cannabis nursery facility on a 220-acre parcel. The project includes the conversion of two existing buildings with sufficient power capacity and abundant water supply. The floor plans include over 10,000 square feet of canopy for “mother” plants and separate clone storage. Additional space will be utilized for flowering plants specifically for research and development.
Bill Hodson, CEO of LiveWire states, "After a lengthy and complicated approval process through all participating California government bodies, we have now received the final approval for this Minor Use Permit. This permit will allow us to begin the build-out process of the two buildings according to our architectural plans, and simultaneously apply for a State License. Due to the amount of detail throughout the permit process, we feel approval from the State will be achieved within a short period of time. We appreciate the detailed work from our legal team and the support we received from the staff in San Luis Obispo County assuring our compliance with local ordinances, and of course the support of the Paso Robles community."
Within the two buildings, the nursery will also contain research and development and staging areas, as well as rooms for cannabis waste, cannabis storage, record keeping, security offices, conference room and additional designated locations required for approval. The facility will be secured via biometric entry locks and comprehensive security features such as motion-sensors, security cameras, exterior lighting that will meet all ordinance standards related to security.
"This will be our second nursery operation in California and will complement our State licenses in Coachella for our high-tech nursery and statewide distribution", added Hodson. "We are now in a position to expedite the implementation of our business plan and accordingly, the financial performance of the Company, to produce a satisfactory ROI for our investors"
About LiveWire Ergogenics, Inc.
LiveWire Ergogenics, Inc. (LVVV) specializes in identifying and monetizing current and future trends in the health and wellness industry. The Company is focused on acquiring, managing and leasing specialized “closed loop” turnkey cannabis real estate locations of fully compliant and permitted turnkey facilities for the production of cannabis-based products and services in California. The Company is also establishing research partnerships to explore the application of cannabinoid-based products to target specific ailments or conditions with large “sufferer” populations for human and veterinarian applications. This includes dosing verification of zero pesticide products for quality brands via its “7X Pure” Cannabis Dosing and Verification System, and the development and licensing of high-quality cannabinoid-based products and services. LiveWire Ergogenics does not sell or distribute products that are in violation of the Unites States Controlled Substance Act.
For more information about LiveWire Ergogenics, visit http://www.livewireergogenics.com. For non-material updates, follow LiveWire Ergogenics on Twitter @livewireLVVV. Download the Stockwatchindex Research Report at www.swiresearch.com/report-index
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and objectives of management for future operations, the development, regulatory approvals and commercialization of the Company’s products, or any of the Company’s other proposed products, systems or services. Such forward-looking statements are not meant to predict or guarantee actual results and performance, events or circumstances, and actual events may differ materially. Factors that may cause actual results to differ materially from any projections may include, without limitation, delays in the development of its products, the impact of significant new or changing government regulation, a potentially negative impact of the continuing conflict between Federal and State laws in the cannabis industry, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s inability to obtain additional financing for the implementation of the Company’s business plans or strategies. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
LIVEWIRE ERGOGENICS INC.
1600 North Kraemer Blvd.
Anaheim, CA 92806
714-740-5144
www.livewireergogenics.com
info@livewireergogenics.com
MARKET AWARENESS
Stockwatchindex, LLC
www.stockwatchindex.com
info@stockwatchindex.com
INVESTOR CONTACT
EquiNet, LLC
Toll free: 877-964-6463
Direct: 858-264-6500
$CANB Canbiola, Inc. (OTCQB: CANB) Announces the Formation of a New Wholly Owned Subsidiary - DuraMed, Inc.
Date : 01/24/2019 @ 11:37AM
Canbiola, Inc. (OTCQB: CANB) Announces the Formation of a New Wholly Owned Subsidiary - DuraMed, Inc.
Canbiola, Inc. (OTCQB: CANB) Announces the Formation of a New Wholly Owned Subsidiary- DuraMed, Inc.
HICKSVILLE, NY -- January 24, 2019 -- InvestorsHub NewsWire -- Canbiola, Inc. (OTCQB: CANB) announces the formation of a new wholly owned subsidiary- DuraMed, Inc.
In an effort to expand its product offering within the medical and wellness segments of the CBD industry, Canbiola has launched DuraMed, Inc., as a wholly owned subsidiary. DuraMed is a medical device company that provides equipment and services to both medical offices as well as direct to consumer. All DuraMed products will be FDA approved, non-invasive, consumer-friendly, and will focus upon aiding in quicker injury recovery as well as pain relief.
In conjunction with this newest vertical, Pure Health Products, Inc. (Pure Health), Canbiola’s laboratory and production facility in Lacey WA, will be supplying DuraMed with its first consumer products. Additionally, Pure Health and Canbiola have just closed an agreement with Hudilab, Inc., to acquire the technology and intellectual property to produce transdermal pads for use with medical devices such as Transcutaneous Electrical Nerve Stimulation (TENS) units. Anyone who has ever suffered from chronic back, knee or joint pain has likely found that the TENS unit technology can deliver pain relief and can be used at home. The technology acquisition from Hudilab provides the ability in infuse the TENS pads with effective dosages of CBD. This technology allows multiple uses of the pads without losing adhesion while allowing the hemp-derived therapeutic compounds (botanicals) in the CBD to attack the pain and be absorbed into the system.
As Canbiola’s CEO Marco Alfonsi says, “This is an incredible breakthrough in pain relief and wellness technology. By taking the proven medical device technology in the TENS unit and combining it with the proprietary CBD compounds developed by Canbiola is truly game-changing!”
According to Hudilab’ s CEO Frank Horwich, “Canbiola is creating a new category of CBD wellness products. Combining CBD with established and well recognized ‘medical devices’, Canbiola is now able to deliver a treatment that delivers the best of both technologies.” Mr. Horwich added, “This positions Canbiola to dominate a newly emerging sector in the CBD via creating new modalities of treatment incorporating CBD and medical devices proven to reduce pain and inflammation.”
According to Mr. Alfonsi, “We believe market conditions are optimal for a CBD delivery system to be combined with the popularity of the TENS units. These CBD infused pads are a technology breakthrough. There are hundreds of thousands of TENS units from scores of manufacturers in use today and the ability to provide the pads with CBD is huge.” Mr. Alfonsi continued, “The Pure Health facility is geared up for major production and expects its first of many orders shortly.”
Lastly Mr. Ferro, President of Pure Health, added, “To have a nationally recognized cannabis industry professional as Mr. Horwich available to Pure Health provides the company with a level of knowledge and an unprecedented technical and practical resource on the new product development team that will facilitate and excite our production plans well into the future.”
Hudilab, Inc. is a Colorado-based new technology developer in the expanding use of industrial hemp derived CBD opportunities. The Hudilab team are leaders in combining the medical benefits CBD with medical technology and improving its effectiveness. The company, as well as Mr. Horwich, have worked in conjunction with some of the largest universities and development laboratories in the USA with expanding the knowledge base and use of cannabis products. Additionally, Hudilab is active with several South American countries in development of hemp opportunities.
About Canbiola, Inc.:
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. The company has already launched several products found at www.canbiola.com.
Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.
CONTACT INFORMATION
Canbiola Investor Relations
Email: IR@canbiola.com
Phone: (516) 595-9544
website: http://www.canbiola.com
Follow us on Twitter and Facebook
$PAOG Tuesday's Cheat Sheet:
https://www.barchart.com/stocks/quotes/PAOG/cheat-sheet
$PAOG Traders Cheat Sheet
https://www.barchart.com/stocks/quotes/PAOG/cheat-sheet
$PAOG Cheat Sheet
https://www.barchart.com/stocks/quotes/PAOG/cheat-sheet
$ACB On Mega Run! Now trading above the 200dma... Very Bullish
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
532
|
Created
|
10/05/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |